[Treatment of coronary heart disease with the beta-1-receptor blocker celiprolol in a long-term study over a 12-month period].
In the present study, the beta-receptor-blocker Celiprolol was tested for its antianginal effects during an observation period of 12 months; 29 patients, both male and female, with definite coronary heart diseases, were subjected to this study. In general Celiprolol was well accepted by the patients, the dosage being 200 mg every morning. Regarding intensity and frequency, the side effects were negligible. It was possible to lower the intensity and frequency of angina attacks considerably during the treatment with Celiprolol. Exercise examinations were carried out at prescribed intervals and showed an increase in pain free working capacity and a decrease in the hypoxic ST-depression on the ECG, also to a considerable extent. The indication for the use of Celiprolol in long-term treatment of coronary heart disease was impressingly confirmed.
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D000787:Angina Pectoris / Q000188:drug therapy; D017272:Celiprolol; D003327:Coronary Disease / Q000188:drug therapy*; D004562:Electrocardiography; D005080:Exercise Test; D005260:Female; D006801:Humans; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D011412:Propanolamines / Q000627:therapeutic use*
D000319:Adrenergic beta-Antagonists; D011412:Propanolamines; D017272:Celiprolol
Behandlung der koronaren Herzkrankheit mit dem Beta-1-Rezeptorenblocker-Celiprolol in einer Langzeitstudie über 12 Monate.